Following EFSA Ban of Food Additive Titanium Dioxide (TiO2), Blue California Launches Clean-label Food Grade Whitening Agents as Alternatives
Rancho Santa Margarita, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Following food authority EFSA’s ban of food additive titanium dioxide (TiO2), Blue California, the producer of natural science-based ingredients, launched novel food-grade whitening agents as a clean-label alternative to replacing potential health risk white colorant titanium dioxide.
“Brands that seek to replace the titanium dioxide white colorant will find many benefits to Blue California’s patent-pending food-grade whitening agents,” said Cuie Yan, Ph.D., vice president of encapsulation. “Our alternative to titanium dioxide is industry-changing with opacifying or whitening effects and excellent sensory benefits with a delicious creamy/rich mouthfeel, and contains proprietary ingredients that may have additional benefits such as supporting cognitive health."
One of the most widely used food pigments is titanium dioxide (E171), an odorless powder that enhances foods' white color or opacity. The most common titanium dioxide products are chewing gum, candies, pastries, chocolates, coffee creamers, and cake decorations. Titanium dioxide is also used as a pigment in paints and medicines.
In recent decades, concerns about the risks of titanium dioxide consumption have grown. The Food and Drug Administration (FDA) categorizes titanium dioxide as Generally Recognized as Safe (GRAS) at a maximum of 1% weight, but other organizations have issued warnings.
New governing rules in Europe are in action for producers to reformulate their products during a six-month window of phasing out titanium dioxide (E171). This follows the food authority European Food Safety Authority (EFSA) decision deeming titanium dioxide (E171) as “not safe” in 2021, and now a complete ban in 2022. France suspended the use of titanium dioxide in January 2020.
“Our clean-label, food-grade, and effective whitening agents are heat and pH stable for a variety of applications that match the performance of titanium dioxide yet overcome its safety concerns,” said Yan. “We’ve innovated these solutions as safe alternatives for brands that need to reformulate products rapidly due to government authorities concerns, bans, and phasing out titanium dioxide.”
Blue California’s patent-pending food-grade whitening powders have a similar size in diameter to the traditional titanium dioxide with higher L values (whiter), as shown in Table 1 below:
Table 1. Color and particle size comparison between Blue California’s novel food-grade whitening agents versus titanium dioxide whitening powder.
|Sample ID||Color Measurement||Redispersion Diameter|
|Titanium Dioxide (reference)||96.06||-0.26||1.54||310.5|
|Novel Food Grade Whitening 1||97.42||-0.09||1.45||266.4|
|Novel Food Grade Whitening 2||97.43||-0.09||1.95||278.2|
|Novel Food Grade Whitening 3||97.48||-0.11||1.43||305.0|
Note: The a and b ‘Color Measurement’ values are color depth markers of red, green, blue, and yellow. The ‘Redispersion Diameter’ measures the particle size.
The food-grade whitening agents have been tested in chewing gum compared to titanium dioxide. The whitening effect results of Blue California’s whitening agents are as remarkable as titanium dioxide. The whiteness increases as the dosage increases.
“We’re ready to collaborate with product developers to replace titanium dioxide with a clean-label, delicious, and safer whitening agents in their product lines,” said Yan.
Blue California is an entrepreneurial, science-based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature-inspired industries.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ahold Delhaize share buyback update16.8.2022 08:00:00 CEST | Press release
Zaandam, the Netherlands, August16, 2022 – Ahold Delhaize has repurchased 254,408 of its common shares in the period from August 8, 2022 up to and including August 12, 2022. The shares were repurchased at an average price of € 27.21 per share for a total consideration of € 6.9 million. These repurchases were made as part of the € 1 billion share buyback program announced on November 15, 2021. The total number of shares repurchased under this program to date is 20,621,088 common shares for a total consideration of € 561.6 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2022/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Sanionas Kv7-program för epilepsi avanceras till leadoptimering16.8.2022 08:00:00 CEST | Pressemelding
PRESSMEDDELANDE 16 augusti 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att bolaget har avancerat sitt lovande Kv7-program för epilepsi till fasen leadoptimering – den sista fasen av läkemedelsupptäckt innan en klinisk kandidat väljs ut. Thomas Feldthus, VD: ”Vi tror att vi har löst knäckfrågorna för att utveckla nästa generation av läkemedelskandidater av den här klassen, och vi ser en betydande potential att ta fram nya banbrytande epilepsibehandlingar. Finansiellt kan uppsidan vara avsevärd, att döma av vissa viktiga läkemedelsavtal som nyligen slutits på Kv7-området.” Miljontals människor runt om i världen påverkas i dag av epilepsi, en sjukdom som kännetecknas av återkommande krampanfall. Det medicinska behovet är stort, eftersom omkring 30 procent av patienterna inte svarar på behandling med konventionella läkemedel mot epilepsi. Läkemedel mot kramper kan desutom ha funktionshämmande biverkningar, som ofta måste minimeras genom no
Saniona progresses its Kv7 epilepsy program into Lead Optimization16.8.2022 08:00:00 CEST | Press release
PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”. Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these. Kv7 ion ch
JULY VOLUME REPORT: STRONG PASSENGER RECOVERY, DROP IN CHANNEL FREIGHT MARKET16.8.2022 07:35:00 CEST | Press release
INVESTOR NEWS no. 24 - 16 August 2022 Ferry – freight: Total volumes in July 2022 were 6.2% below 2021. Activity was overall robust in freight markets except for parts of the Baltic Sea region and the Channel Dover Strait corridor. North Sea volumes were overall below 2021 as UK routes were on level while routes between Sweden and the Continent were below 2021. The latter decrease was due to lower automotive and paper volumes as well as high activity for these segments last year in July. Volumes in the Mediterranean network continued to grow reflecting a high level of Turkish industrial production and exports. Channel’s volumes were below 2021 following a decrease in total market volumes. Baltic Sea’s volumes were below 2021 due to the war in Ukraine. Volumes were mainly lower between Germany and Lithuania. For the last twelve months 2022-21, the total transported freight lane metres decreased 0.6% to 43.6m from 43.9m in 2021-20. Ferry – passenger: The number of passengers increased fi
JULI MÆNGDERAPPORT: STÆRKT PASSAGEROPSVING, NEDGANG I KANALENS FRAGTMARKED16.8.2022 07:35:00 CEST | pressemeddelelse
INVESTOR NEWS nr. 24 - 16. august 2022 Færge – fragt: De samlede mængder i juli 2022 var 6,2% lavere end i 2021. Aktiviteten var generelt robust på fragtmarkederne bortset fra dele af Østersø-regionen og Kanalens Doverstræde. North Seas mængder var samlet set lavere end i 2021, da ruterne til Storbritannien var på niveau, mens ruterne mellem Sverige og kontinentet var lavere end i 2021. Sidstnævnte nedgang skyldtes lavere bil- og papirmængder samt høj aktivitet for disse segmenter sidste år i juli. Mediterraneans mængder fortsatte med at stige, hvilket afspejler en fortsat høj tyrkisk industriproduktion og eksport. Channels mængder var lavere end i 2021 som følge af en nedgang i det samlede markeds mængder. Baltic Seas mængder var lavere end i 2021 på grund af krigen i Ukraine. Mængderne var primært lavere mellem Tyskland og Litauen. For de sidste 12 måneder 2022-21 var der en nedgang i det samlede antal transporterede fragt-lanemeter på 0,6% til 43,6 mio. fra 43,9 mio. i 2021-20. Færg